Sanyou Biopharmaceuticals Co., Ltd. (“Sanyou Bio”) announced the completion of a Series C financing round of nearly RMB 100 million. The round was exclusively invested by the Zero2IPO Industry Investment Fund under Zero2IPO Group, reinforcing the company’s strategy of building an AI‑powered open innovation system for the R&D and commercialization of innovative drugs.
Financing Milestone
| Item | Detail |
|---|---|
| Company | Sanyou Biopharmaceuticals Co., Ltd. (“Sanyou Bio”) |
| Round | Series C |
| Amount | Nearly RMB 100 million |
| Investor | Zero2IPO Industry Investment Fund (under Zero2IPO Group) – exclusive |
| Announcement Date | 9 Nov 2026 |
| Headquarters | Shanghai, China |
| Use of Proceeds | Not disclosed |
| Valuation | Not disclosed |
Company Profile & Technology Platform
- Business Focus: R&D and commercialization of innovative drugs.
- AI‑STAL: The company’s globally leading intelligent ultra‑trillion molecular library serves as the source of innovation.
- SAI‑DA: A dry‑wet integrated intelligent new drug accelerator functions as the core engine of discovery.
- Clicklinks: An open innovation system built atop AI‑STAL and SAI‑DA, connecting discovery assets with external partners.
- Global Footprint: Business centers established across Asia, North America, Europe, and other regions, forming a global business network.
- Infrastructure: More than 20,000 square meters of R&D and GMP facilities currently in operation and planned.
Industry Context – AI Drug Discovery Funding
- Dry‑Wet Integration: Platforms that couple computational (“dry”) modeling with experimental (“wet”) validation are a defining trend in AI drug discovery, aiming to close the loop between prediction and synthesis‑testing cycles.
- Ultra‑Large Chemical Space: Molecular libraries at the trillion scale expand the searchable chemical space far beyond conventional compound collections, supporting de novo design against diverse targets.
- Strategic Investor Profile: Zero2IPO Group is a leading Chinese healthcare investment and research platform; its Industry Investment Fund’s exclusive participation signals institutional conviction in Sanyou Bio’s platform model.
Market Impact & Outlook
- Capital Validation: Closing a Series C round of nearly RMB 100 million in a disciplined funding environment underscores investor confidence in the company’s AI‑driven discovery engine and commercialization strategy.
- Scaling Capacity: Proceeds are expected to support expansion of the 20,000+ square meter R&D and GMP footprint and further development of the AI‑STAL / SAI‑DA / Clicklinks technology stack.
- Global Commercialization: With business centers across Asia, North America, and Europe, Sanyou Bio is positioning its open innovation system for cross‑border partnering and licensing opportunities.
- Financial Impact: The transaction is a private financing; no revenue contribution or valuation figures were disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Sanyou Bio’s use of Series C proceeds, expansion of its R&D and GMP facilities, development of its AI‑driven platforms, and global commercialization plans. Actual results may differ due to risks including the pace of drug discovery programs, regulatory review of clinical candidates, competitive dynamics in AI drug discovery, and access to future financing.-Fineline Info & Tech
